A Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SYH2062 Injection in Healthy Chinese Volunteers
Latest Information Update: 08 May 2025
At a glance
- Drugs SYH 2062 (Primary)
- Indications Hypertension
- Focus Adverse reactions
- Sponsors CSPC Zhongnuo Pharmaceutical
Most Recent Events
- 30 Apr 2025 Planned number of patients changed from 42 to 46.
- 24 Mar 2025 Status changed from not yet recruiting to recruiting.
- 28 Feb 2025 New trial record